Table 4.
Analyte and Variable Importance Scores (Scaled) Estimated From Elastic Net Penalization Are Reported in Order of Importance for Each Comparison Using Unstimulated and Background-adjusted Values
| Control vs Incident | Control vs Prevalent | Prevalent vs Incident | Control vs Combined |
|---|---|---|---|
| Unstimulated | |||
| CCL3 (100) | IFN-γ (100) | IL-2 (100) | IFN-γ (100) |
| CCL4 (26) | IL-2 (78) | EGF (28) | IL-2 (56) |
| IFN-α2 (20) | TNF (19) | IFN-γ (10) | IFN-α2 (38) |
| TNF (16) | CCL3 (18) | CCL4 (9) | CCL4 (13) |
| IL-10 (12) | IFN-α2 (11) | TGF-α (6) | TGF-α (12) |
| IL-2 (8) | CXCL10 (7) | sCD40L (1) | IL-1α (6) |
| EGF (6) | IL-1α (6) | TNF (1) | EGF (5) |
| VEGF (5) | IL-10 (5) | VEGF (4) | |
| IFN-γ (4) | sCD40L (5) | sCD40L (3) | |
| sCD40L (4) | VEGF (2) | IL-10 (2) | |
| CXCL10 (1) | TGF-α (2) | CCL3(1) | |
| IL-1α (1) | EGF (1) | TNF (1) | |
| Background-adjusted, Stimulated-unstimulated | |||
| CCL3 (100) | CXCL10 (100) | IFN-α2 (100) | IFN-γ (100) |
| CXCL10 (57) | CCL4 (59) | CCL4 (59) | TNF (77) |
| IL-2 (52) | IL-2 (58) | sCD40L (53) | IFN-α2 (62) |
| IFN-γ (47) | TGF-α (35) | IFN-γ (40) | EGF (52) |
| TNF (40) | sCD40L (31) | IL-10 (38) | IL-1α (46) |
| CCL4 (34) | VEGF (20) | VEGF (14) | IL-10 (38) |
| IL-1α (32) | IFN-γ (20) | EGF (11) | VEGF (36) |
| IFN-α2 (26) | CCL3 (19) | IL-2 (11) | CXCL10 (33) |
| VEGF (19) | TNF (14) | TGF-α (10) | sCD40L (32) |
| EGF (11) | IL-1α (14) | IL-1α (9) | CCL4 (28) |
| sCD40L (5) | IFN-α2 (12) | CXCL10 (1) | TGF-α (18) |
| IL-10 (1) | IL-10 (3) | IL-2 (3) |
Analytes that do not appear had a variable importance score of 0.
Bold items are analytes that were found to be significant for prediction >20% of the time.
Abbreviations: CXCL10, C-X-C motif chemokine 10; CCL, chemokine (C-C motif) ligand; EGF, epidermal growth factor; IFN, interferon; IL, interleukin; sCD40L, soluble CD40 ligand; TGF-α, transforming growth factor-α; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.